COCP | tickerfilter.com

Fundamental analysis

21%

Profitability 0%

Dept financing 5%

Liquidity 50%

Performance 40%

Company vs Stock growth

N/A

1.700 1.770

0.070 4.12%

+ Add row to compare

Performance

5 Days

-10.64%

1 Month

-22.22%

3 Months

-47.65%

6 Months

-29.21%

1 Year

-19.23%

2 Year

-42.20%

Key data

Stock price

$1.26

P/E Ratio

0.00

DAY RANGE

$1.25 - $1.39

EPS

-$1.87

52 WEEK RANGE

$1.25 - $3.26

52 WEEK CHANGE

-$18.71

MARKET CAP

17.906 M

YIELD

N/A

SHARES OUTSTANDING

10.174 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-12-2025

BETA

0.14

PUBLIC FLOAT

AVERAGE 10 VOLUME

$21,192

AVERAGE 30 VOLUME

$19,461

Company detail

CEO: Sam Lee
Region: US
Website: cocrystalpharma.com
Employees: 10
IPO year: 2014

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Cocrystal Pharma, Inc. focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection.

COCP - Cocrystal Pharma, Inc.